Payment overview · 2025
General Payments
$917.08
16 reported records · 6 companies
Healthcare provider profile · identity verified
Stephen Keith Smith, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MORGANTON, NC · NPI 1982646923
Verified facts
What the public records show
CMS Open Payments records show Stephen Keith Smith, M.D. received $917.08 in general payments during 2025 across 16 reported records.
Novartis Pharmaceuticals Corporation accounted for 61.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 171 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Tresiba by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $563.56 | 61.5% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $162.03 | 17.7% | 8 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $123.98 | 13.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $38.74 | 4.2% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.75 | 1.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.02 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $702.65 | 15 |
| Travel and Lodging | $214.43 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $123.98 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $83.02 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $79.01 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $38.74 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $30.47 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
90 | 76 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
171 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1118 | 232 |
| Atorvastatin Calcium | Atorvastatin Calcium | 635 | 158 |
| Omeprazole | Omeprazole | 494 | 109 |
| Lisinopril | Lisinopril | 473 | 108 |
| Pantoprazole Sodium | Pantoprazole Sodium | 445 | 93 |
| Alprazolam | Alprazolam | 419 | 57 |
| Amlodipine Besylate | Amlodipine Besylate | 395 | 84 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 385 | 53 |
| Escitalopram Oxalate | Escitalopram Oxalate | 376 | 71 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 355 | 76 |
| Hydrochlorothiazide | Hydrochlorothiazide | 290 | 70 |
| Metoprolol Succinate | Metoprolol Succinate | 288 | 61 |
| Gabapentin | Gabapentin | 285 | 61 |
| Eliquis | Apixaban | 267 | 42 |
| Losartan Potassium | Losartan Potassium | 266 | 59 |
| Diclofenac Sodium | Diclofenac Sodium | 261 | 52 |
| Tramadol Hcl | Tramadol Hcl | 256 | 54 |
| Clonazepam | Clonazepam | 254 | 33 |
| Furosemide | Furosemide | 231 | 57 |
| Oxycodone Hcl | Oxycodone Hcl | 226 | 29 |
| Potassium Chloride | Potassium Chloride | 221 | 43 |
| Meloxicam | Meloxicam | 219 | 46 |
| Lorazepam | Lorazepam | 215 | 39 |
| Allopurinol | Allopurinol | 211 | 51 |
| Zolpidem Tartrate | Zolpidem Tartrate | 208 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 197 | 41 |
| Glimepiride | Glimepiride | 189 | 50 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 187 | 36 |
| Jardiance | Empagliflozin | 183 | 34 |
| Simvastatin | Simvastatin | 181 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 172 | 27 |
| Ozempic | Semaglutide | 171 | 28 |
| Prednisone | Prednisone | 169 | 69 |
| Metoprolol Tartrate | Metoprolol Tartrate | 161 | 35 |
| Metformin Hcl | Metformin Hcl | 153 | 44 |
| Trazodone Hcl | Trazodone Hcl | 150 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 146 | 28 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 146 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 135 | 29 |
| Famotidine | Famotidine | 132 | 29 |
| Montelukast Sodium | Montelukast Sodium | 131 | 27 |
| Mounjaro | Tirzepatide | 131 | 22 |
| Celecoxib | Celecoxib | 130 | 23 |
| Donepezil Hcl | Donepezil Hcl | 128 | 21 |
| Pregabalin | Pregabalin | 127 | 14 |
| Spironolactone | Spironolactone | 127 | 31 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 124 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 103 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 103 | 12 |
| Synthroid | Levothyroxine Sodium | 102 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 96 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 94 | 33 |
| Ropinirole Hcl | Ropinirole Hcl | 93 | 20 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 90 | 76 |
| Ondansetron Hcl | Ondansetron Hcl | 86 | 27 |
| Xarelto | Rivaroxaban | 86 | 17 |
| Estradiol | Estradiol | 83 | 19 |
| Valsartan | Valsartan | 83 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 82 | 28 |
| Ezetimibe | Ezetimibe | 82 | 19 |
| Sertraline Hcl | Sertraline Hcl | 82 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 79 | 16 |
| Carvedilol | Carvedilol | 75 | 18 |
| Warfarin Sodium | Warfarin Sodium | 70 | 16 |
| Diazepam | Diazepam | 65 | 14 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 65 | 11 |
| Benazepril Hcl | Benazepril Hcl | 63 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 61 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 61 | 15 |
| Memantine Hcl | Memantine Hcl | 61 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 61 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 60 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 57 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 56 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | suppressed |
| Levofloxacin | Levofloxacin | 54 | 37 |
| Promethazine Hcl | Promethazine Hcl | 54 | 11 |
| Fenofibrate | Fenofibrate | 49 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | 11 |
| Fluconazole | Fluconazole | 47 | 30 |
| Lansoprazole | Lansoprazole | 47 | suppressed |
| Telmisartan | Telmisartan | 47 | suppressed |
| Entresto | Sacubitril/Valsartan | 45 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 45 | 16 |
| Ondansetron Odt | Ondansetron | 45 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 44 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 31 |
| Fenofibrate | Fenofibrate Nanocrystallized | 44 | suppressed |
| Rybelsus | Semaglutide | 44 | suppressed |
| Repatha Sureclick | Evolocumab | 43 | suppressed |
| Torsemide | Torsemide | 43 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 43 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 42 | suppressed |
| Topiramate | Topiramate | 42 | suppressed |
| Cefdinir | Cefdinir | 41 | 27 |
| Trintellix | Vortioxetine Hydrobromide | 41 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 40 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 40 | 31 |
| Novolog Flexpen | Insulin Aspart | 39 | 14 |
| Linzess | Linaclotide | 38 | suppressed |
| Azithromycin | Azithromycin | 37 | 32 |
| Colestipol Hcl | Colestipol Hcl | 37 | suppressed |
| Myrbetriq | Mirabegron | 37 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 35 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Clonidine | Clonidine | 34 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Trimethoprim | Trimethoprim | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | suppressed |
| Etodolac | Etodolac | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | suppressed |
| Ramipril | Ramipril | 33 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 32 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 32 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Temazepam | Temazepam | 32 | suppressed |
| Finasteride | Finasteride | 31 | suppressed |
| Nystatin | Nystatin | 31 | 16 |
| Ipratropium Bromide | Ipratropium Bromide | 30 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 30 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Oxycontin | Oxycodone Hcl | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Verapamil Er | Verapamil Hcl | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 22 |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 27 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 22 |
| Primidone | Primidone | 26 | suppressed |
| Xtampza Er | Oxycodone Myristate | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Risperidone | Risperidone | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Cephalexin | Cephalexin | 23 | 19 |
| Morphine Sulfate Er | Morphine Sulfate | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Triazolam | Triazolam | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 15 |
| Baclofen | Baclofen | 21 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 11 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 15 |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 14 |
| Sucralfate | Sucralfate | 17 | suppressed |
| Testosterone | Testosterone | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Armodafinil | Armodafinil | 16 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 16 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 16 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 16 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 16 | suppressed |
| Ssd | Silver Sulfadiazine | 16 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Felodipine Er | Felodipine | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 14 |
| Praluent Pen | Alirocumab | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Zaleplon | Zaleplon | 13 | suppressed |
| Cartia Xt | Diltiazem Hcl | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Leflunomide | Leflunomide | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Tresiba | Insulin Degludec | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $917.08 · 16 records | Novartis Pharmaceuticals Corporation | AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, FARXIGA, INSPIRE, TRELEGY ELLIPTA | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error